Pyxis Oncology Inc
Company Profile
Business description
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Contact
321 Harrison Avenue
BostonMA02118
USAT: +1 617 221-9059
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
56
Stocks News & Analysis
stocks
Updating our assumed commodity prices and fair values of the two largest Aussie miners
stocks
Do AI labs like Anthropic and OpenAI have economic moats?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,937.00 | 59.30 | 0.67% |
| CAC 40 | 7,832.88 | 29.55 | 0.38% |
| DAX 40 | 25,277.68 | 190.41 | 0.76% |
| Dow JONES (US) | 51,850.55 | 195.60 | 0.38% |
| FTSE 100 | 10,656.28 | 104.23 | 0.99% |
| HKSE | 24,271.20 | 59.85 | 0.25% |
| NASDAQ | 27,245.90 | 120.27 | -0.44% |
| Nikkei 225 | 69,030.92 | 11.19 | -0.02% |
| NZX 50 Index | 13,775.71 | 51.91 | -0.38% |
| S&P 500 | 7,807.24 | 4.30 | -0.06% |
| S&P/ASX 200 | 8,783.20 | 66.60 | 0.76% |
| SSE Composite Index | 3,797.24 | 16.55 | -0.43% |